Merus Labs International Stock Price, News & Analysis (NASDAQ:MSLI)

$1.30 0.00 (0.00 %)
(As of 12/14/2017 08:16 AM ET)
Previous Close$1.30
Today's Range$1.29 - $1.30
52-Week Range$0.70 - $1.33
Volume9,400 shs
Average Volume56,140 shs
Market Capitalization$153.19 million
P/E RatioN/A
Dividend YieldN/A
Beta1.56

About Merus Labs International (NASDAQ:MSLI)

Merus Labs International logoMerus Labs International Inc. is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company's products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin. Elantan are tablets or capsules that belong to a group of medicines called organic nitrates. Isoket belongs to a group of medicines called organic nitrates. Deponit belongs to a group of medicines called nitrates. Sintrom is an anticoagulant indicated to treat and prevent thromboembolic diseases. Emselex/Enablex is used in adults to treat overactive bladder syndrome. Surgestone is used to treat women with menstrual irregularities due to ovulation disorder, dysmenorrhea and premenstrual syndrome. Provames is used as hormone replacement therapy in postmenopausal women with symptoms of estrogen deficiency.

Receive MSLI News and Ratings via Email

Sign-up to receive the latest news and ratings for MSLI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Generic Pharmaceuticals
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:MSLI
CUSIPN/A
Phone+1-905-7260995

Debt

Debt-to-Equity Ratio0.50%
Current Ratio0.80%
Quick Ratio0.54%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS($0.09)
Net IncomeN/A
Net Margins-5.18%
Return on Equity-2.51%
Return on Assets-1.32%

Miscellaneous

Employees13
Outstanding Shares117,360,000

Merus Labs International (NASDAQ:MSLI) Frequently Asked Questions

What is Merus Labs International's stock symbol?

Merus Labs International trades on the NASDAQ under the ticker symbol "MSLI."

How were Merus Labs International's earnings last quarter?

Merus Labs International Inc (NASDAQ:MSLI) released its quarterly earnings results on Monday, August, 10th. The company reported ($0.01) EPS for the quarter, missing the Zacks' consensus estimate of $0.02 by $0.03. The business had revenue of $7.73 million for the quarter, compared to analyst estimates of $17.19 million. Merus Labs International had a negative return on equity of 2.51% and a negative net margin of 5.18%. View Merus Labs International's Earnings History.

Where is Merus Labs International's stock going? Where will Merus Labs International's stock price be in 2017?

5 analysts have issued 1-year target prices for Merus Labs International's shares. Their forecasts range from $1.00 to $1.65. On average, they anticipate Merus Labs International's share price to reach $1.35 in the next twelve months. View Analyst Ratings for Merus Labs International.

Who are some of Merus Labs International's key competitors?

Who are Merus Labs International's key executives?

Merus Labs International's management team includes the folowing people:

  • Michael S. Cloutier, Independent Chairman of the Board
  • , Bio & Compensation - 
  • Barry Fishman, Chief Executive Officer, Director
  • , Bio & Compensation - 
  • Michael Scott Bumby, Chief Financial Officer
  • Robert McLay, Vice President - Sales and Marketing
  • , Bio & Compensation - 
  • Frank Rotmann, Vice President and Head of European Operations
  • , Bio & Compensation - 
  • Robert Bloch M.D., Director
  • , Bio & Compensation - 
  • Theresa Sheila Firestone, Independent Director
  • , Bio & Compensation - 
  • David D. Guebert CPA, Independent Director
  • , Bio & Compensation - 
  • Robert S. Pollock, Independent Director
  • , Bio & Compensation - 
  • Timothy G. Sorensen, Independent Director
  • , Bio & Compensation - 

How do I buy Merus Labs International stock?

Shares of Merus Labs International can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Merus Labs International's stock price today?

One share of Merus Labs International stock can currently be purchased for approximately $1.30.

How big of a company is Merus Labs International?

Merus Labs International has a market capitalization of $153.19 million. Merus Labs International employs 13 workers across the globe.

How can I contact Merus Labs International?

Merus Labs International's mailing address is 100 Wellington St. West Suite 2110 Stn Toronto Dom PO Box 151, TORONTO, ON M5K 1H1, Canada. The company can be reached via phone at +1-905-7260995.


MarketBeat Community Rating for Merus Labs International (MSLI)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  129 (Vote Outperform)
Underperform Votes:  125 (Vote Underperform)
Total Votes:  254
MarketBeat's community ratings are surveys of what our community members think about Merus Labs International and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Merus Labs International (NASDAQ:MSLI) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.252.252.30
Ratings Breakdown: 0 Sell Rating(s)
6 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $1.35$3.88$3.88$3.61
Price Target Upside: 77.87% upside411.20% upside411.20% upside376.19% upside

Merus Labs International (NASDAQ:MSLI) Consensus Price Target History

Price Target History for Merus Labs International (NASDAQ:MSLI)

Merus Labs International (NASDAQ:MSLI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/11/2017Canaccord GenuityDowngradeHold$1.65LowView Rating Details
2/13/2017Bloom BurtonReiterated RatingHoldN/AView Rating Details
12/16/2016ScotiabankReiterated RatingSector Perform$1.75 -> $1.25N/AView Rating Details
12/16/2016Paradigm CapitalReiterated RatingHold$1.60 -> $1.00N/AView Rating Details
12/15/2016CIBCReiterated RatingOutperform -> Neutral$2.40 -> $1.50N/AView Rating Details
11/8/2016CitigroupReiterated RatingNeutralN/AView Rating Details
6/13/2016WedbushReiterated RatingOutperformN/AView Rating Details
6/13/2016GuggenheimReiterated RatingBuyN/AView Rating Details
2/5/2016MackieReiterated RatingHold$1.90 -> $2.30N/AView Rating Details
2/5/2016Dundee SecuritiesReiterated RatingBuy$3.50 -> $3.60N/AView Rating Details
(Data available from 12/14/2015 forward)

Earnings

Merus Labs International (NASDAQ:MSLI) Earnings History and Estimates Chart

Earnings by Quarter for Merus Labs International (NASDAQ:MSLI)

Merus Labs International (NASDAQ MSLI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/14/2017Q117($0.02)($0.04)$23.18 million$19.53 millionViewListenView Earnings Details
8/10/2015Q3 2015$0.02($0.01)$17.19 million$7.73 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Merus Labs International (NASDAQ:MSLI) Earnings Estimates

2017 EPS Consensus Estimate: ($0.01)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.01)($0.01)($0.01)
Q2 20171($0.01)($0.01)($0.01)
Q3 20171$0.00$0.00$0.00
Q4 20171$0.01$0.01$0.01
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Merus Labs International (NASDAQ:MSLI)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Merus Labs International (NASDAQ MSLI)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Merus Labs International (NASDAQ MSLI) News Headlines

Source:
DateHeadline
Financial Survey: Merus Labs International (NASDAQ:MSLI) and The Medicines (MDCO)Financial Survey: Merus Labs International (NASDAQ:MSLI) and The Medicines (MDCO)
www.americanbankingnews.com - August 14 at 10:10 PM
Merus Labs International Inc (NASDAQ:MSLI) Receives Consensus Recommendation of "Hold" from AnalystsMerus Labs International Inc (NASDAQ:MSLI) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - August 4 at 7:44 AM
Analyzing Merus Labs International (MSLI) and The Medicines (MDCO)Analyzing Merus Labs International (MSLI) and The Medicines (MDCO)
www.americanbankingnews.com - July 20 at 8:42 AM
Norgine B.V. completes acquisition of Merus Labs International Inc. strengthening its leading position in the European specialist pharma marketNorgine B.V. completes acquisition of Merus Labs International Inc. strengthening its leading position in the European specialist pharma market
finance.yahoo.com - July 18 at 6:27 AM
Featured Company News - A Majority of Merus Labs Shareholders Approve Acquisition by Dutch Pharma Major Norgine B.V.Featured Company News - A Majority of Merus Labs' Shareholders Approve Acquisition by Dutch Pharma Major Norgine B.V.
finance.yahoo.com - July 14 at 6:37 AM
$0.01 Earnings Per Share Expected for Merus Labs International Inc. (NASDAQ:MSLI) This Quarter$0.01 Earnings Per Share Expected for Merus Labs International Inc. (NASDAQ:MSLI) This Quarter
www.americanbankingnews.com - July 13 at 8:13 AM
Merus Labs International Inc. Receives Court Approval in Connection with Proposed Plan of Arrangement with Norgine B.V.Merus Labs International Inc. Receives Court Approval in Connection with Proposed Plan of Arrangement with Norgine B.V.
finance.yahoo.com - July 13 at 7:03 AM
Merus Labs International Inc. Shareholders Approve Plan of Arrangement with Norgine B.V.Merus Labs International Inc. Shareholders Approve Plan of Arrangement with Norgine B.V.
finance.yahoo.com - July 11 at 2:31 AM
Merus Labs International Inc. (NASDAQ:MSLI) Given Consensus Recommendation of "Hold" by AnalystsMerus Labs International Inc. (NASDAQ:MSLI) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - July 10 at 9:55 AM
Pro-Trader Daily: Corporate News Blog - Norgines Acquisition of Merus Labs Crosses Final Hurdle as Spanish Anti-Trust Agency Okays the DealPro-Trader Daily: Corporate News Blog - Norgine's Acquisition of Merus Labs Crosses Final Hurdle as Spanish Anti-Trust Agency Okays the Deal
www.finanznachrichten.de - July 7 at 7:34 AM
Merus Labs International Inc. and Norgine B.V. receive Spanish anti-trust approval of proposed ArrangementMerus Labs International Inc. and Norgine B.V. receive Spanish anti-trust approval of proposed Arrangement
finance.yahoo.com - July 3 at 9:40 PM
BRIEF-Merus Labs International mails letter to shareholdersBRIEF-Merus Labs International mails letter to shareholders
www.reuters.com - June 27 at 11:48 PM
Merus Labs (MSLI) to be Acquired by Norgine B.V. for $1.65/ShareMerus Labs (MSLI) to be Acquired by Norgine B.V. for $1.65/Share
www.streetinsider.com - May 12 at 12:12 AM
BRIEF-Merus Labs announces changes to stock option plan to address ISS recommendationBRIEF-Merus Labs announces changes to stock option plan to address ISS recommendation
www.reuters.com - March 13 at 10:14 AM
3:28 am Merus Labs responds to media reports suggesting co is exploring strategic alternatives; confirms using Rothschild & Co to evaluate options3:28 am Merus Labs responds to media reports suggesting co is exploring strategic alternatives; confirms using Rothschild & Co to evaluate options
us.rd.yahoo.com - March 1 at 6:45 PM
Merus Labs Internationals (MSLI) CEO Barry Fishman on Q1 2017 Results - Earnings Call TranscriptMerus Labs International's (MSLI) CEO Barry Fishman on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - February 14 at 8:44 PM
Merus Labs slumps 15% on fiscal year-end and Q4 results; modest growth in non-GAAP earnings expectedMerus Labs slumps 15% on fiscal year-end and Q4 results; modest growth in non-GAAP earnings expected
seekingalpha.com - December 15 at 12:22 AM
Merus Labs Intl (MSLI) to Acquire Three Cardiovascular Products from UCB in EUR 92M DealMerus Labs Int'l (MSLI) to Acquire Three Cardiovascular Products from UCB in EUR 92M Deal
www.streetinsider.com - February 2 at 2:12 PM

SEC Filings

Merus Labs International (NASDAQ:MSLI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Merus Labs International (NASDAQ:MSLI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Merus Labs International (NASDAQ MSLI) Stock Chart for Thursday, December, 14, 2017

Loading chart…

This page was last updated on 12/14/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.